IOBT Description — IO Biotech Inc
IO Biotech is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on its T-win technology platform. Co.'s product candidates are designed to induce the immune system to simultaneously target and disrupt various pathways that regulate tumor-induced immunosuppression. Co.'s main product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. In addition to IO102, IO103 and IO112, Co. is evaluating additional candidates that have potential for use in solid tumors.
|
Free IOBT Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Strong Buy (3.83 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|